Navigation Links
JDRF to provide $1M in funding to SmartCells, Inc.

New York, NY and Beverly, MA [October 22, 2008] ~ The Juvenile Diabetes Research Foundation (JDRF) and SmartCells, Inc. today announced a partnership to advance SmartCells' SmartInsulin for the treatment of type 1 diabetes. SmartInsulin will be a once-a-day, glucose-regulated insulin that is administered by injection just under the skin. But unlike currently available insulins, SmartInsulin is designed to maintain continuous, tight control of blood glucose levels while reducing the risk of hypoglycemia like the pancreas does automatically in the absence of diabetes. As part of the agreement, JDRF will provide $1 million in first-year funding to support preclinical safety and efficacy testing. The partnership is structured to support milestone-based funding through proof-of-concept human clinical trials.

"JDRF's support will accelerate the commercial development of our SmartInsulin therapy for type 1 diabetes. Our formulation is designed to address the most critical issue in diabetes treatment achieving tight glucose control without inducing severe hypoglycemic episodes. To accomplish this, patients will only have to inject SmartInsulin once a day using the same needles currently used for conventional insulin. We expect these important treatment benefits will improve patient safety and quality of life while reducing diabetic complications," said Todd C. Zion, Ph.D., President and CEO of SmartCells. "We are very pleased to have JDRF's support for this program, and share their commitment to the development of breakthrough treatments for type 1 diabetes."

Aaron Kowalski, Ph.D., Director of JDRF's Metabolic Control Program, explained that JDRF is committed to supporting the development of unique therapies that can improve metabolic control for people with type 1 diabetes: "We believe that glucose-regulated insulin may represent a practical solution to the real needs of people with diabetes, and this collaboration illustrates our dedication to accelerating the pace of science leading to cures and treatments for people with type 1 diabetes by helping innovative companies test concepts and bring their products to patients faster."

Under the terms of the partnership, the $1 million grant will support testing the safety and efficacy of SmartInsulin in preclinical type 1 diabetes trials. The partnership is intended to accelerate the product's development and reduce the time needed to progress to human testing. The grant is part of JDRF's innovative Industry Discovery and Development Partnership Program, which supports companies developing drugs, treatments, and technologies to address type 1 diabetes and its complications.


Contact: Leslie Schwartz
Juvenile Diabetes Research Foundation International

Related biology news :

1. identiMetrics & BIO-key(R) Provide Biometric Finger Scanning for School Food Service Nationwide
2. Volcanoes may have provided sparks and chemistry for first life
3. MU brain imaging center provides research for autism, schizophrenia and Parkinsons disease
4. Brain structure provides key to unraveling function of bizarre dinosaur crests
5. Digital zebrafish embryo provides the first complete developmental blueprint of a vertebrate
6. Study provides insight on a common heart rhythm disorder
7. Field Museum provides gold standard for mammal survey
8. Paleozoic sediment curve provides new tool for tracking sea-floor sediment movements
9. Anabolic steroids provide a competitive edge in power lifting years after doping has ended
10. Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution
11. 1-hit event provides new opportunity for colon cancer prevention, say Fox Chase researchers
Post Your Comments:
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
(Date:10/23/2015)... and GOLETA, California , ... HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce a ... eye tracking data captured during interactive real-world tasks ... and play integration of their established wearable solutions for ... to synchronize gaze behavior captured with SMI Eye ...
(Date:10/22/2015)... SAN JOSE, Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ... results for its first quarter ended September 30, 2015. ... first quarter of fiscal 2016 grew 66 percent over the comparable ... quarter of fiscal 2016 was $23.8 million, or $0.62 per diluted ... net income for the first quarter of fiscal 2016 grew 39 ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... ... 25, 2015 , ... Jessica Richman and Zachary Apte, founders ... initial angel funding process. Now, they are paying it forward to other microbiome ... investments in the microbiome space. In this, they join other successful entrepreneurs-turned-angels ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
Breaking Biology Technology: